I

Inhibikase Therapeutics
D

IKT

1.56000
USD
0.04
(2.43%)
مغلق
حجم التداول
5,214
الربح لكل سهم
-1
العائد الربحي
-
P/E
3
حجم السوق
189,176,590
الأخبار المقالات

العنوان: Inhibikase Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.